Skip to content

Clinical trials

Phase 2/3 Diabetes Mellitus, Type 1 trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Diabetes Mellitus, Type 1 Phase: Phase 2/3 Clear all

46 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20052
20063
20072
20081
20092
20101
20121
20131
20144
20152
20161
20173
20182
20193
20201
20213
20221
20232
20243
20251
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed30
Recruiting5
Terminated3
Unknown status3
Active, not recruiting2
Withdrawn2
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Ain Shams University5
Hvidovre University Hospital4
McGill University Health Centre/Research Institute of the McGill University Health Centre4
Brigham and Women's Hospital2
Eli Lilly and Company2
Jaeb Center for Health Research2
Massachusetts General Hospital2
Assistance Publique - Hôpitaux de Paris1
Azienda Ospedaliero Universitaria Maggiore della Carita1
Ben-Gurion University of the Negev1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Diabetes Mellitus, Type 146
Insulin Resistance8
Diabetes Mellitus6
Diabetes Mellitus, Type 24
Hypoglycemia4
Kidney Diseases2
Atherosclerosis1
Cardiovascular Diseases1
Diabetes Complications1
Diabetic Nephropathies1

Trials

Showing 26 to 46 of 46. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.